Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia

Clinical Interventions in Aging

Volumn 6, Issue 1, 2011, Pages 161-172

  Yoshida, Masaki ^a   Kudoh, Junzo ^a   Homma, Yukio ^b   Kawabe, Kazuki ^c  

^a KUMAMOTO ROSAI HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO TEISHIN HOSPITAL   (Japan)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Selective; Silodosin

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; NAFTOPIDIL; PHENYLEPHRINE; PLACEBO; PRAZOSIN; SILODOSIN; TAMSULOSIN;

CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; LOOSE FECES; LOWER URINARY TRACT SYMPTOM; MORNING DOSAGE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; REVIEW; SIDE EFFECT; THIRST; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE;

EID: 80755143278     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/cia.s13803     Document Type: Review

References (44)

1. American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH). 2010. Chapter 1: Guideline on the management of benign prostatic hyperplasia (BPH). Available from: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?subcbph. Accessed May 13, 2011.
2. Wasserman NF. Benign prostatic hyperplasia: A review and ultrasound classification. Radiol Clin North Am. 2006:44:689-710.
3. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361:1359-1367.
4. Roehrborn CG, McConnell JD. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi LR, Novick AC, et al, editors. Campbell-Walsh Urology. 9th ed. Philadelphia, PA: WB Saunders; 2007.
5. Emberton M, Cornel EB, Bassi PF, et al. Benign prostatic hyperplasia as a progressive disease: A guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62:1076-1086.
6. Fine SR, Ginsberg P. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: Issues and potential complications. J Am Osteopath Assoc. 2008;108:333-337.
7. Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective alpha1A-adrenergic antagonist. Urology. 1998;51:861-872.
8. O'Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications. Urology. 2003;62 Suppl 1:15-23.
9. Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2008;77:1403-1410.
10. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193-199.
11. Hieble JP, Bylund DB, Clarke DE, et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev. 1995;47:267-270.
12. Schwinn DA, Johnston GI, Page SO, et al. Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: Sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995;272:134-142.
13. Hawrylyshyn KA, Michelotti GA, Coge F, et al. Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol Sci. 2004;25:449-455.
14. Price DT, Lefkowitz RJ, Caron MG, et al. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: Implications for human alpha-adrenergic physiology. Mol Pharmacol. 1994;45:171-175.
15. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150:546-551.
16. Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997;30:202-215.
17. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150:546-551.
18. 1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol. 1998;123:1289-1293.
19. 1-adrenergic receptors by vessel bed and age. Circulation. 1999;100:2336-2343.
20. Souverein PC, Van Staa TP, Egberts ACG, De la Rosette JJMH, Cooper C, Leufkens HG. Use of C-blockers and the risk of hip/femur fractures. J Int Med. 2003;254:548-554.
21. 1-adrenoceptors and native tissues. Mol Pharmacol. 1955;48:250-258.
22. Yamazaki Y. Development of silodosin. Yakugaku Zasshi. 2006;126:207-208.
23. 1-Adrenoceptor subtype selectivity and organ specificity of Silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:209-216.
24. 1-adreneergic receptor subtypes by molecular modeling. Life Sci. 2002;71:2531-2541.
25. Tatemichi S, Kobayashi K, Maruyama I, et al. Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats-study of the selectivity for lower urinary tract. Yakugaku Zasshi. 2006;126:217-223.
26. 1a-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther. 1999;291:81-91.
27. 1A-adrenoceptor selective antagonist for treating benign prostatic hyperplasia: Results of a Phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019-1024.
28. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1 A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 Phase III studies. J Urol. 2009;181:2634-2640.
29. Chapple CR, Montorsi F, Tammela TJ, Wirth M, Koldewijn E, Fernandez EF; European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo-and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59:342-352.
30. 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia: Phase III long-term study. Jap J Urol Surg. 2006;19:153-164.
31. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: A 9-month, open-label extension study. Urology. 2009;74:1318-1322.
32. 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010;29:558-562.
33. Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R. Efficacy of silodosin for relieving benign prostatic obstruction: Prospective pressure flow study. J Urol. 2009;182:2831-2835.
34. Miyakita H, Yokoyama E, Onodera Y, et al. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol. 2010;17:869-875.
35. 1-Adrenoceptors and ejaculatory function. Br J Pharmacol. 2007;152:289-290.
36. 1A-blocker in normal volunteers. J Sex Med. 2008;5:2185-2190.
37. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: Minimizing morbidity caused by treatment. Urology. 2003;62 Suppl 3A:24-33.
38. 1-Adrenoceptors are required for normal male sexual function. Br J Pharmacol. 2007;152:332-340.
39. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006;13:1311-1316.
40. Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011;14:143-148.
41. Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology. 2010;76:1446-1450.
42. 1-adrenergic receptor antagonists. Isr Med Assoc J. 2009;11:42-44.
43. Oshika T, Ohashi Y, Inamura M, et al. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical i1-adrenoceptor antagonist. Am J Ophthalmol. 2007;143:150-151.
44. United State Food and Drug Administration/Center for Drug Evaluation and Research. Drug Approval Package, RAPAFLO (silodosin) capsules, Application No. 022206. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000TOC.cfm. Accessed on April 1, 2011.